Literature DB >> 3013215

Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins.

B Casu, G Diamantini, G Fedeli, M Mantovani, P Oreste, R Pescador, R Porta, G Prino, G Torri, G Zoppetti.   

Abstract

Heparin preparations with different anticoagulant and antilipemic (fat-clearing) activities were oxidized with periodate under conditions of cleavage of all the C(2)-C(3) bonds of non-sulfated uronic acid residues, while preserving the original molecular weight of the polysaccharide. Periodate-oxidised heparins (oxyheparins, O-HEP) and the corresponding borohydride-reduced products (reduced oxyheparins, RO-HEP) were compared with the original heparins for their content in trisulfated disaccharide sequences (as determined by 13C-nuclear magnetic resonance) and in active sites for antithrombin-III (as determined indirectly by affinity chromatography), and for their anticoagulant and antilipemic (lipoprotein lipase-releasing) activities. The drop of anticoagulant activity induced by periodate oxidation was paralleled by a substantial decrease of affinity for antithrombin, and is thought to arise from glycol splitting at the level of the D-glucuronic acid residue that is part of the active site for antithrombin. The trisulfated disaccharide sequences and the associated antilipemic activities were substantially unaffected by periodate oxidation. The residual anticoagulant activity of periodate-oxidized heparins obtained from preparations - such as those from beef lung - rich in trisulfated disaccharide sequences is discussed in terms of the influence of charge density on heparin-protease interactions not mediated by antithrombin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013215

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

Review 1.  Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Authors:  Nicole L Blanchette; David H Manz; Frank M Torti; Suzy V Torti
Journal:  Expert Rev Hematol       Date:  2015-12-15       Impact factor: 2.929

2.  Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus.

Authors:  Beatrice Mercorelli; Pasqua Oreste; Elisa Sinigalia; Giulia Muratore; David Lembo; Giorgio Palù; Arianna Loregian
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

Review 3.  Borrelia burgdorferi glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease.

Authors:  Yi-Pin Lin; Lingyun Li; Fuming Zhang; Robert J Linhardt
Journal:  Microbiology       Date:  2017-11-08       Impact factor: 2.777

4.  Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides.

Authors:  Anna Alekseeva; Benito Casu; Giangiacomo Torri; Sabrina Pierro; Annamaria Naggi
Journal:  Anal Biochem       Date:  2012-11-29       Impact factor: 3.365

5.  Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor.

Authors:  D Coltrini; M Rusnati; G Zoppetti; P Oreste; G Grazioli; A Naggi; M Presta
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

Review 6.  Heparin Mimetics: Their Therapeutic Potential.

Authors:  Shifaza Mohamed; Deirdre R Coombe
Journal:  Pharmaceuticals (Basel)       Date:  2017-10-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.